hide
Free keywords:
ACUTE MYELOID-LEUKEMIA; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE;
TRANSCRIPTIONAL NETWORKS; STEM; GENE; REPRESSOR; PROTEINS; GFI-1;
AUTOREGULATION; SPECIFICATIONHematology;
Abstract:
Growth factor independence 1 (GFI1) is a DNA-binding transcription factor and a key regulator of hematopoiesis. GFI1-36N is a germ line variant, causing a change of serine (S) to asparagine (N) at position 36. We previously reported that the GFI1-36N allele has a prevalence of 10% to 15% among patients with acute myeloid leukemia (AML) and 5% to 7% among healthy Caucasians and promotes the development of this disease. Using a multiomics approach, we show here that GFI1-36N expression is associated with increased frequencies of chromosomal aberrations, mutational burden, and mutational signatures in both murine and human AML and impedes homologous recombination (HR)-directed DNA repair in leukemic cells. GFI1-36N exhibits impaired binding to N-Myc downstream-regulated gene 1 (Ndrg1) regulatory elements, causing decreased NDRG1 levels, which leads to a reduction of O6-methylguanine-DNA-methyltransferase (MGMT) expression levels, as illustrated by both transcriptome and proteome analyses. Targeting MGMT via temozolomide, a DNA alkylating drug, and HR via olaparib, a poly-ADP ribose polymerase 1 inhibitor, caused synthetic lethality in human and murine AML samples expressing GFI1-36N, whereas the effects were insignificant in nonmalignant GFI1-36S or GFI1-36N cells. In addition, mice that received transplantation with 36N leukemic cells treated with a combination of temozolomide and olaparib had significantly longer AML-free vival than mice that received transplantation with GFI1-36S leukemic cells. This suggests that reduced expression leaves GFI1-36N leukemic cells particularly vulnerable to DNA damage initiating chemotherapeutics. data provide critical insights into novel options to treat patients with AML carrying the GFI1-36N variant.
